We are live on ! Find out more
IOBT

IO Biotech
IOBT

Delisted

IOBT was delisted on the 6th of April, 2026.

Back to rankings

18 hedge funds and large institutions have $72.2M invested in IO Biotech in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.06% more ownership

Funds ownership: 51.56% → 53.62% (+2.1%)

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

5% less funds holding

Funds holding: 19 → 18 (-1)

6% less capital invested

Capital invested by funds: $76.9M → $72.2M (-$4.7M)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

Holders
18
Holders Change
-1
Holders Change %
-5.26%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
3
Reduced
3
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
+$4.88M
2
BCM
Bridgeway Capital Management
Texas
+$459K
3
Citadel Advisors
Citadel Advisors
Florida
+$88.3K
4
Morgan Stanley
Morgan Stanley
New York
+$46.7K
5
UBS Group
UBS Group
Switzerland
+$13.7K

Top Sellers

Rank Fund Capital Flow
1
SB
Samsara BioCapital
California
-$686K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$330K
3
Millennium Management
Millennium Management
New York
-$162K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$141K
5
Norges Bank
Norges Bank
Norway
-$133K

IOBT Hedge Fund Activity: Q2 2022 in Review

18 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in IO Biotech (IOBT) for Q2 2022, worth a combined $72.2M — down 6.1% from $76.9M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of IOBT and 5 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 3 added.

The largest buyer was PFM Health Sciences, adding an estimated $4.88M. The largest seller was Samsara BioCapital, cutting an estimated $686K.

  • 18 institutional investors held IO Biotech (IOBT) as of Q2 2022, down from 19 in Q1 2022.
  • Funds reported $72.2M of IO Biotech stock for Q2 2022, down 6.1% quarter-over-quarter.
  • 5 funds opened new IO Biotech positions in Q2 2022 and 6 closed out, a net change of -1 holder.
  • The largest IO Biotech buyer in Q2 2022 was PFM Health Sciences, an estimated $4.88M added.
  • The largest IO Biotech seller in Q2 2022 was Samsara BioCapital, an estimated $686K sold.

Based on aggregated 13F filings for Q2 2022.